Image 1_Exploration of the diagnostic and prognostic roles of decreased autoantibodies in lung cancer.tif by Ying Ye (72583)

“…Almost all the TAAbs applied for diagnosis are those elevated, however, there are still large numbers of autoantibodies detected to decrease in tumor serums, and their functions were rarely known. …”

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Association of each health behavior and the reported decrease in psychological well-being during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors.... by Elie Mulhem (22537863)

Subjects:

Effect of each health behavior on the reported decrease in physical health during the pandemic between individuals who often/very often compared to rarely/never engaged in health behaviors.... by Elie Mulhem (22537863)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Loss of <i>Rab23</i> decreases ciliation in MEFs and Tbr1 + intermediate progenitors. by Wan Ying Leong (22075947)

K1 expression decreases in HA15 treated cells. by Guillermo Najarro (19964572)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Cancer virtual patients with decreased initial neutrophil concentrations have higher viral load peaks. by Sonia T. Gazeau (21512764)

“…<p><b>A)</b> Viral loads in mild <b>a</b><b>-c)</b> and severe virtual patients <b>d</b><b>-f)</b>. <b>B)</b> Sensitivity analysis determined that decreasing <i>N</i>0 (the initial concentration of neutrophils) causes higher peak viral load and peak IL-6 and IFN concentrations.…”

Plots of FEV₁ (upper left), FVC (upper right), TLC (lower left) and TLCO (lower right) values expressed in % pred. (<i>y</i>-axis) against <i>z</i>-scores (<i>x</i>-axis... by Piotr W. Boros (21446186)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…If power was above the threshold (<i>z</i> > 1.96) for a minimum of 10% of the time window (500 ms) after the cue, the channel was considered hemifield-selective. …”